The future of high-grade glioma: Where we are and where are we going

MarcC Chamberlain,EmilieLe Rhun,Sophie Taillibert

DOI: https://doi.org/10.4103/2152-7806.151331

2015-01-01

Surgical Neurology International

Abstract:High-grade glioma (HGG) are optimally treated with maximum safe surgery, followed by radiotherapy (RT) and/or systemic chemotherapy (CT). Recently, the treatment of newly diagnosed anaplastic glioma (AG) has changed, particularly in patients with 1p19q codeleted tumors. Results of trials currenlty ongoing are likely to determine the best standard of care for patients with noncodeleted AG tumors. Trials in AG illustrate the importance of molecular characterization, which are germane to both prognosis and treatment. In contrast, efforts to improve the current standard of care of newly diagnosed glioblastoma (GB) with, for example, the addition of bevacizumab (BEV), have been largely disappointing and furthermore molecular characterization has not changed therapy except in elderly patients. Novel approaches, such as vaccine-based immunotherapy, for newly diagnosed GB are currently being pursued in multiple clinical trials. Recurrent disease, an event inevitable in nearly all patients with HGG, continues to be a challenge. Both recurrent GB and AG are managed in similar manner and when feasible re-resection is often suggested notwithstanding limited data to suggest benefit from repeat surgery. Occassional patients may be candidates for re-irradiation but again there is a paucity of data to commend this therapy and only a minority of selected patients are eligible for this approach. Consequently systemic therapy continues to be the most often utilized treatment in recurrent HGG. Choice of therapy, however, varies and revolves around re-challenge with temozolomide (TMZ), use of a nitrosourea (most often lomustine; CCNU) or BEV, the most frequently used angiogenic inhibitor. Nevertheless, no clear standard recommendation regarding the prefered agent or combination of agents is avaliable. Prognosis after progression of a HGG remains poor, with an unmet need to improve therapy.

What problem does this paper attempt to address?

This paper aims to explore the future treatment directions of high - grade glioma (HGG). Specifically, it attempts to address the following main issues:

1. **Current treatment standards and their limitations**:
- The paper reviews the current standard treatment methods for HGG, including maximal safe surgical resection followed by radiotherapy (RT) and/or systemic chemotherapy (CT). For newly diagnosed anaplastic glioma (AG), especially tumors with 1p19q co - deletion, the treatment methods have already changed.
- However, for AG without 1p19q co - deletion, the optimal standard treatment plan has not been determined yet, and ongoing clinical trials may provide the answers.

2. **The role of molecular characteristics in treatment**:
- The importance of molecular characteristics (such as 1p19q co - deletion, IDH1 mutation, MGMT promoter methylation, etc.) for prognosis and treatment selection is increasingly prominent.
- Especially in AG, molecular characteristics not only help predict the prognosis of patients but also guide treatment selection.

3. **Treatment challenges for newly diagnosed glioblastoma (GB)**:
- Although attempts have been made to improve the treatment effect of GB by adding bevacizumab (BEV) and other methods, the results are not satisfactory.
- New treatment methods, such as vaccine - based immunotherapy, are being explored in multiple clinical trials.

4. **Management of recurrent HGG**:
- Recurrent HGG is an inevitable problem for almost all HGG patients. Current management strategies include re - operation, re - radiotherapy, and systemic treatment.
- However, the effectiveness and safety of these methods are still controversial and need more clinical data support.

5. **Future research directions**:
- The paper discusses future research directions, including the development of new molecular targets, immunotherapy, and other innovative treatment methods.
- It emphasizes the necessity of further research to improve the prognosis and quality of life of HGG patients.

In general, this paper attempts to propose future research directions by reviewing the current treatment progress and challenges faced, in the hope of finding more effective treatment methods for HGG.